Johnson & Johnson initiates second global Phase 3 clinical trial of its Janssen COVID-19 vaccine candidate

The Phase 3 ENSEMBLE study of the single-dose regimen of JNJ-78436735, the investigational vaccine candidate for the prevention of COVID-19 being developed by the Janssen Pharmaceutical Companies of Johnson & Johnson, continues to enroll and vaccinate study participants. ENSEMBLE is proceeding to enroll up to 60,000 participants worldwide.
Source: World Pharma News - Category: Pharmaceuticals Tags: Featured Johnson & Business and Industry Source Type: news